

ORIGINAL ARTICLE

Identification of novel endophenaside antibiotics produced by *Kitasatospora* sp. MBT66

Changsheng Wu^{1,2}, Gilles P van Wezel^{1,3} and Young Hae Choi^{2,3}

Actinomycetes are a major source of bioactive secondary metabolites and are a focal point in the search for novel antimicrobial compounds that are needed to combat multidrug-resistant pathogens. Here, we report the discovery of several novel phenazine-type antibiotics produced by *Kitasatospora* sp. MBT66. These include the novel glycosylated endophenazines A–E (1–5), together with *N*-prenylated endophenazine F1 (6). Compounds 1 and 3 contain a 2'-*O*-methylation of the sugar moiety, which is rare in nature and reported for the first time in connection with phenazines. The structures of the new compounds were determined on the basis of their spectral data, including 1D and 2D NMR, HR-MS and the gene cluster responsible for the biosynthesis of phenazines was identified. All phenazine derivatives showed antimicrobial activity against the Gram-positive *Bacillus subtilis*, while compounds 1–3 and 5 also inhibited growth of the Gram-negative *Escherichia coli*.

The Journal of Antibiotics (2015) 68, 445–452; doi:10.1038/ja.2015.14; published online 18 February 2015

INTRODUCTION

Infections caused by multiple drug-resistant bacteria are a major threat to human health, both in the nosocomial environment and in the general community.^{1–3} It has become increasingly difficult to find novel antibiotics with efficacy against multidrug-resistant pathogens such as multidrug-resistant *Mycobacterium tuberculosis*, methicillin-resistant *Staphylococcus aureus* and multidrug-resistant Gram-negative pathogens.³ Indeed, despite intensive screening programs in the pharmaceutical industry, hardly any new drugs have been identified in this millennium, which underlines the urgent need for novel approaches to find antimicrobial drugs.⁴ Actinomycetes are Gram-positive mycelial bacteria with a complex multicellular life style.^{5,6} They are industrially highly relevant because of their ability to produce a plethora of natural products, including anticancer, antifungal, anthelmintic and antibacterial drugs.⁷ Of all known naturally occurring antibiotics, some two-third is derived from actinomycetes, the majority of which are produced by streptomycetes.⁸ Sequencing of *Streptomyces* genomes established the presence of silent antibiotic biosynthetic gene clusters, suggesting that the potential of these organisms for novel drug production is much larger than originally anticipated.⁹ As an example, many novel gene clusters were identified even in the extensively studied model streptomycetes such as *S. coelicolor*,¹⁰ *S. griseus*¹¹ and *S. lividans*.¹² This has led to novel approaches to identifying specific conditions or agents that elicit the expression of antibiotics.^{13–15}

In a recent study, we screened a collection of over 800 actinomycetes using 40 different growth conditions, which identified among others *Kitasatospora* sp. MBT66 that was shown to be a prolific

producer of antibiotics with activity against Gram-positive and Gram-negative pathogens.¹⁶ Preliminary analysis predicted that it produced a number of compounds exhibiting similar chemical properties (TLC and HPLC-UV detection) to 1-carbomethoxy phenazine that was described in another actinomycete *Streptomyces* sp. MBT70.¹⁶ The phenazines are a group of heterocyclic, nitrogen-containing compounds isolated primarily from *Pseudomonas* and *Streptomyces* bacteria.¹⁷ They differ in chemical and physical properties according to the nature and/or position of functionalities, and thus give rise to a full spectrum of colors ranging from the deep red to the light blue.¹⁸ Phenazines are redox-active and can reduce molecular oxygen, leading to the generation of toxic reactive oxygen species and explaining their broad-spectrum antibiotic activity toward bacteria, fungi and plant and animal tissues.^{19,20} Clofazimine is an example of a phenazine compound that is successfully applied in the clinic, where it is used for the treatment of leprosy, while clofazimine also has efficacy against the multidrug-resistant *Mycobacterium tuberculosis*.²¹ In addition, phenazines have multiple roles in the producing bacteria for survival and interaction with the environment, such as protection of plants by rhizobacteria against bacterial and fungal pathogens,²² reducing environmental Fe³⁺ to the more soluble Fe²⁺ to aid iron acquisition²³ and in primary energy metabolism by mediating the reoxidation of NADH and utilization of pyruvate under oxygen-limiting conditions.²⁴ Although more than 6000 phenazine-containing compounds have been described over the past century, fewer than 100 are of natural origin.²⁵

Very few glycosylated phenazines have so far been found in nature, and these are without exception compounds with bioactivity that are

¹Molecular Biotechnology, Institute of Biology, Leiden University, Leiden, The Netherlands and ²Natural Products Laboratory, Institute of Biology, Leiden University, Leiden, The Netherlands

³Shared senior authors.

Correspondence: Professor GP van Wezel, Molecular Biotechnology, Institute of Biology, Leiden University, Sylviusweg 72, Leiden 2333 BE, The Netherlands.

E-mail: g.wezel@biology.leidenuniv.nl

Received 19 November 2014; revised 12 January 2015; accepted 21 January 2015; published online 18 February 2015

derived from 6-deoxy-L-glycopyranosides.²⁰ In this work, we report the isolation, structure determination and antimicrobial activity of novel glycosylated endophenazines (1–5) and an *N*-prenylated endophenazine (6) produced by *Kitasatospora* species MBT66, and present the gene cluster responsible for their biosynthesis.

MATERIALS AND METHODS

General experimental procedures

FT-IR was measured on Perkin-Elmer FT-IR Spectrometer Paragon 1000 (Perkin-Elmer, Waltman, MA, USA). UV measurements were performed using a Shimadzu UV mini-1240. NMR spectra were recorded in CH₃OH-*d*₄ on a Bruker DMX 500 MHz NMR and 600 MHz calibrated to a residual methanol-*d*₄ at δ 3.30. HR-ESI-MS were collected on an Agilent 1200 series HPLC connected to a LTQ-Orbitrap spectrometer. Semi-preparative HPLC (pHPLC) was performed with a Shimadzu HPLC system and a 5-ml Rheodyne manual injection loop, equipped with a reversed-phase C18 column (Phenomenex Luna C18 (2) 100 A 5 micron 250 × 10 mm, Phenomenex, Torrance, CA, USA). All the pHPLC experiments used 2 ml min⁻¹ flow rate and fraction collection based on detected peak. TLC was performed with silica gel 60 (Merck, Darmstadt, Germany) plates using CHCl₃/MeOH (10:1) and visualized

with anisaldehyde/sulfuric acid reagent. All solvents and chemicals were of analytical and HPLC grade.

Microorganisms and culture conditions

Kitasatospora sp. MBT66 was isolated from Himalayan mountain soil as described previously.¹⁶ Cultivation was done as described previously.²⁶ For solid-grown cultures, minimal media agar plates (MM) with glycerol and mannitol (1% w/v) as the carbon sources were used. Square agar plates (12 cm × 12 cm) were inoculated with 5 × 10⁷ spores from a fresh spore suspension. In total 125 plates were used, and incubated at 30 °C for 6 days. *Escherichia coli* K12 and *Bacillus subtilis* 168 were used for screening of antimicrobial activity.

Extraction and isolation

Kitasatospora sp. MBT66 was fermented by stationary cultivation with a total volume of 5 l agar medium. After fermentation for 6 days, mycelia were combined and extracted with ethyl acetate by soaking in solvent overnight at room temperature. The extraction was evaporated under reduced pressure to obtain 2.0 g of a crude residue. This extract adsorbed by silica gel was first chromatographed on a Macroporous resin Diaion HP-20 from Supelco (Bellefonte, PA, USA) by eluting stepwise from H₂O to MeOH. For monitoring, 20 μ l of each fraction was subjected to TLC on premade silica gel plates (Merck)




Figure 1 Phenazine derivatives from *Kitasatospora* sp. MBT66. Compounds 1–5 are glycosylated endophenazines, compound 6 is an *N*-prenylated endophenazine. Compounds 1 and 3 were methylated at the 2'-*O* position of the rhamnose moiety.

Table 1 ¹H NMR data for compounds 1–6

NO.	1	2	3	4	5	6
2	8.88 (dd, <i>J</i> = 7.2, 1.2 Hz, 1H)	8.27 (dd, <i>J</i> = 7.0, 1.0 Hz, 1H)	8.29 (dd, <i>J</i> = 7.0, 1.0 Hz, 1H)	8.30 (dd, <i>J</i> = 7.0, 1.0 Hz, 1H)	8.38 (dd, <i>J</i> = 7.0, 1.5 Hz, 1H)	7.51 (dd, <i>J</i> = 7.2, 1.2 Hz, 1H)
3	8.07 (dd, <i>J</i> = 9.0, 7.2 Hz, 1H)	8.00 (dd, <i>J</i> = 8.5, 7.0 Hz, 1H)	8.02 (dd, <i>J</i> = 8.5, 7.0 Hz, 1H)	8.02 (dd, <i>J</i> = 7.5, 7.0 Hz, 1H)	8.02 (dd, <i>J</i> = 7.5, 7.0 Hz, 1H)	7.79 (dd, <i>J</i> = 8.4, 7.2 Hz, 1H)
4	8.54 (dd, <i>J</i> = 9.0, 1.2 Hz, 1H)	8.41 (dd, <i>J</i> = 8.5, 1.0 Hz, 1H)	8.43 (dd, <i>J</i> = 8.5, 1.0 Hz, 1H)	8.42 (dd, <i>J</i> = 7.5, 1.0 Hz, 1H)	8.46 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H)	7.68 (dd, <i>J</i> = 8.4, 1.2 Hz, 1H)
6		8.10 (dd, <i>J</i> = 9.0, 1.5 Hz, 1H)	8.12 (dd, <i>J</i> = 9.0, 1.5 Hz, 1H)	8.15 (dd, <i>J</i> = 7.0, 1.0 Hz, 1H)	8.01 (m, 1H)	6.19 (d, <i>J</i> = 2.4 Hz, 1H)
7	7.69 (dd, <i>J</i> = 7.2, 0.6 Hz, 1H)	7.91 (dd, <i>J</i> = 9.0, 7.0 Hz, 1H)	7.93 (dd, <i>J</i> = 9.0, 7.0 Hz, 1H)	7.98 (dd, <i>J</i> = 7.5, 7.0 Hz, 1H)	8.02 (m, 1H)	
8	7.97 (dd, <i>J</i> = 9.0, 7.2 Hz, 1H)	7.81 (dd, <i>J</i> = 6.5, 1.0 Hz, 1H)	7.83 (dd, <i>J</i> = 6.5, 1.0 Hz, 1H)	8.16 (dd, <i>J</i> = 7.5, 1.0 Hz, 1H)	8.28 (m, 1H)	6.88 (d, <i>J</i> = 2.4 Hz, 1H)
9	8.15 (dd, <i>J</i> = 9.0, 0.6 Hz, 1H)				8.01 (m, 1H)	
1'	6.03 (d, <i>J</i> = 1.2 Hz, 1H)	6.41 (d, <i>J</i> = 1.5 Hz, 1H)	6.56 (d, <i>J</i> = 1.5 Hz, 1H)	6.43 (d, <i>J</i> = 1.5 Hz, 1H)	6.39 (d, <i>J</i> = 1.5 Hz, 1H)	3.83 (d, <i>J</i> = 7.8 Hz, 2H)
2'	4.04 (dd, <i>J</i> = 2.4, 1.8 Hz, 1H)	4.15 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H)	3.81 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H)	4.27 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H)	4.13 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H)	5.49 (m, 1H)
3'	4.28 (dd, <i>J</i> = 9.6, 3.6 Hz, 1H)	3.75 (dd, <i>J</i> = 9.5, 3.5 Hz, 1H)	3.80 (dd, <i>J</i> = 9.5, 3.5 Hz, 1H)	3.79 (dd, <i>J</i> = 9.5, 3.5 Hz, 1H)	4.01 (dd, <i>J</i> = 9.5, 3.5 Hz, 1H)	
4'	3.52 (dd, <i>J</i> = 10.2, 9.6 Hz, 1H)	3.53 (t, <i>J</i> = 9.5 Hz, 1H)	3.48 (t, <i>J</i> = 9.5 Hz, 1H)	3.58 (t, <i>J</i> = 9.5 Hz, 1H)	3.60 (t, <i>J</i> = 9.5 Hz, 1H)	1.78 (s, 3H)
5'	3.81 (m, 1H)	3.83 (m, 1H)	3.80 (m, 1H)	3.82 (m, 1H)	4.21 (m, 1H)	1.73 (s, 3H)
6'	1.26 (d, <i>J</i> = 6.0 Hz, 3H)	1.35 (d, <i>J</i> = 6.5 Hz, 3H)	1.33 (d, <i>J</i> = 6.0 Hz, 3H)	1.33 (d, <i>J</i> = 6.5 Hz, 3H)	1.39 (d, <i>J</i> = 6.0 Hz, 3H)	
7'	3.64 (s, 3H)		3.63 (s, 3H)			
1''		4.25 (dd, <i>J</i> = 15.5, 7.5 Hz, 1H);	4.27 (dd, <i>J</i> = 15.5, 7.5 Hz, 1H);	7.89 (d, <i>J</i> = 16.0 Hz, 1H)		5.17 (d, <i>J</i> = 5.4 Hz, 2H)
		4.18 (dd, <i>J</i> = 15.5, 2.5 Hz, 1H)	4.20 (dd, <i>J</i> = 15.5, 2.5 Hz, 1H)			
2''		5.86 (m, 1H)	5.87 (m, 1H)	7.12 (d, <i>J</i> = 16.0 Hz, 1H)		5.45 (m, 1H)
4''		1.88 (s, 3H)	1.89 (s, 3H)	1.54 (s, 3H)		1.98 (s, 3H)
5''		4.01 (s, 2H)	4.02 (s, 2H)	1.53 (s, 3H)		4.00 (s, 2H)

Recorded in CD₃OD. ¹H NMR spectra of 2–5 were recorded at 500 MHz, 1, 6 at 600 MHz. Proton coupling constants (*J*) in Hz are given in parentheses. All chemical shift assignments were done on the basis of 1D and 2D NMR techniques.

by using developing solvent system of chloroform and methanol (10:1). The 40% (v/v) methanol eluent showing interesting bands on TLC and moderate antibiotic activity in paper disc agar diffusion test with bacterium *B. subtilis*, was subsequently separated by silica gel (pore size 60 Å, 70–230 mesh, St Louis, MO, USA) column chromatography employing gradient elution from CHCl₃ to MeOH, to give four subfractions (sfr.1–sfr.4). Sfr.2 was rechromatographed on Sephadex LH-20 (Sigma) column, to purify the compound 2 (2.5 mg) and compound 6 (0.2 mg). Semi-preparative reversed-phase HPLC (Phenomenex Luna C18 (2) 100 Å 5 μm 250 × 10 mm) purification of sfr.1, eluting with a gradient of MeOH in H₂O from 80–100% in 30 min, gave the pure compound 3 (*t*_R = 30.25 min, 0.3 mg) and 4 (*t*_R = 29.10 min, 0.2 mg). Separation of sfr.3 by HPLC using the gradient of MeOH in H₂O from 50–80% in 30 min resulted in the purification of 5 (*t*_R = 21.25 min, 1.3 mg), and 7 (*t*_R = 28.50 min, 0.2 mg). Sfr.4 was similarly subjected to pHPLC employing the mobile phase MeOH in H₂O from 50–80% in 30 min and led to the separation of 1 (*t*_R = 17.7 min, 0.35 mg).

Antimicrobial activity assays

Antimicrobial activity was determined basically following the methods described in reference.²⁷ The respective compound (1–7) was dissolved in methanol (2 mg ml⁻¹), and 25 μl of the solution was applied on a paper disk (*d* = 6 mm). The disks were then placed onto an agar plate containing a soft agar overlay with either *B. subtilis* or *E. coli*. Ampicillin and streptomycin were used as positive controls, and the solvent methanol as the negative control. After incubation at 37 °C for 18 h, growth inhibition zones (in mm) were recorded as antimicrobial activity.

RESULTS AND DISCUSSION

We previously performed a screen of a collection of some 800 actinomycetes obtained from mountain soils, so as to identify optimal laboratory conditions for antimicrobial secondary metabolites production.¹⁶ *Kitasatospora* sp. MBT66²⁸ was one of our 96 most prolific antibiotic-producing identified actinomycetes,¹⁶ which was selected for further phytochemical investigation. Preliminary TLC detection of the crude extract of compounds produced by *Kitasatospora* sp. MBT66 on MM agar plates showed several yellow UV-active spots (254 nm) and orange fluorescence at 366 nm, which turned reddish-brown by staining with anisaldehyde/sulfuric acid reagent. Repeated chromatographic separation of upscaled extracts (2.0 g) coupled with subsequent spectroscopy data analysis resulted in the characterization of five previously undescribed rhamnosylated phenazines, endophenazines A–E (1–5) and one *N*-prenylated phenazine endophenazine F1 (6) with minor yield, together with the previously identified 1-carbomethoxy phenazine (7).¹⁶ The structures of the compounds are presented in Figure 1.

Resolution of the endophenazine structures

Compound 1 was obtained as a yellowish solid with a molecular formula of C₂₀H₂₁N₃O₆ established from high resolution mass [M + H]⁺ peak at *m/z* 400.15076. The ¹H NMR (600 MHz, CH₃OH-*d*₄) of 1 (Table 1) showed six aromatic protons in two 1,2,3-trisubstituted aromatic spin systems, via δ_H 8.88 (dd, *J* = 7.2, 1.2, Hz, H-2), 8.07 (dd, *J* = 9.0, 7.2 Hz, H-3), and 8.54 (dd, *J* = 9.0, 1.2 Hz, H-4), along with 7.69 (dd, *J* = 7.2, 0.6 Hz, H-7), 7.97 (dd, *J* = 9.0, 7.2 Hz, H-8), and 8.15 (dd, *J* = 9.0, 0.6 Hz, H-9). Five protons in the range of δ_H 6.0–3.50, together with one methyl doublet at δ_H 1.26 (d, *J* = 6.0 Hz, H₃-6') in high-magnetic field constituted another spin system by the confirmation of COSY experiment, which suggested the existence of a 6-deoxyhexapyranose sugar moiety (Figure 2). In addition, one distinct methoxyl δ_H 3.64 (s, H₃-7') was identified in the sugar region. The APT spectrum of compound 1 (Table 2) revealed 20 signals, which were assigned to carbonyl δ_C 168.7 (C-11), one oxygenated *sp*² carbon δ_C 152.8 (C-6), six *sp*² aromatic methine




Figure 2 HMBC and COSY correlations of new phenazine derivatives. Key HMBC (○) and ^1H - ^1H COSY (■) NMR correlations of new phenazine derivatives are presented.

Table 2 ^{13}C NMR data for compounds 1–6

NO.	1	2	3	4	5	6
1	130.1	132.7	131.3	131.4	132.2	145.5
2	136.2	132.3	132.9	132.7	133.5	122.7
3	130.6	130.5	130.5	130.7	130.2	134.6
4	135.0	133.3	132.5	133.1	133.9	114.7
4a	143.1	142.9	142.1	142.1	143.5	132.1
5a	137.8	143.3	143.1	143.6	143.6	139.8
6	152.8	127.7	127.1	127.8	132.4	98.6
7	114.8	132.7	132.8	132.7	132.5	185.8
8	133.0	130.6	130.5	128.0	129.7	132.3
9	123.5	142.0	141.3	137.0	132.4	146.6
9a	143.7	144.4	143.6	142.1	144.7	146.8
10a	141.7	140.6	140.2	140.3	141.8	133.4
11	168.7	166.2	166.0	165.6	166.7	175.8
1'	97.9	96.4	93.0	96.2	96.4	29.9
2'	81.5	70.9	80.4	70.5	70.7	122.1
3'	71.8	71.7	71.2	71.3	71.5	135.7
4'	73.7	73.1	72.9	72.7	72.8	25.9
5'	70.9	72.4	72.0	72.2	72.2	18.0
6'	17.7	17.9	17.5	17.7	17.6	
7'	59.3		59.2			
1''		29.5	29.1	121.3		47.1
2''		124.1	123.7	142.7		117.2
3''		137.6	137.1	71.7		142.8
4''		13.7	13.4	29.2		14.3
5''		68.4	68.0	29.2		67.3

carbons δ_{C} 136.2 (C-2), 130.6 (C-3), 135.0 (C-4), 114.8 (C-7), 133.0 (C-8) and 123.5 (C-9) and five sp^2 quaternary carbons (δ_{C} 130.1 (C-1), 143.1 (C-4a), 137.8 (C-5a), 143.7 (C-9a) and 141.7 (C-10a)). Five oxygenated methine carbons δ_{C} 97.9 (C-1'), 81.5 (C-2'), 71.8 (C-3'), 73.7 (C-4') and 70.9 (C-5'), together with one methyl group δ_{C} 17.7 (C-6'), were corresponding to the 6-deoxyhexapyranose by HSQC and APT spectra. The final structure of compound **1** was determined by analyses of the 2D NMR spectra (^1H - ^1H COSY, HSQC and HMBC). The HMBC spectrum of compound **1** also suggested that it contained a 6-hydroxy-phenazine-1-carboxylic acid aglycone (H-2/C-11, C-10a, C-4; H-3/C-1; H-4/C-4a, C-2; H-7/C-9, C-6, C-5a; H-8/C-9a, C-6; and H-9/C-10a, C-7 and C-5a). The aglycone was also confirmed by comparison of the spectral data with the literature.^{29–31} Analysis of the COSY spectrum revealed one contiguous spin system formed by correlations of five oxygen-bearing methines and one doublet methyl signal at δ_{H} 1.39, confirming the deoxyhexapyranose. The connectivity of the 6-deoxysugar to the aglycone was confirmed from the HMBC long-range coupling of H-8 (δ_{H} 7.97) and H-1' (δ_{H} 6.03) to the C-6 (δ_{C} 152.8) of the phenazine nucleus. The additional characteristic methoxy group was attached onto C-2', based on two key HMBC correlation H-2'/C-7' and H₃-7'/C-2' (Figure 2). The key HMBC correlation H-2/C-11 (δ_{C} 168.7) established a carbonyl substituent at C-1. To satisfy the molecular formula $\text{C}_{20}\text{H}_{21}\text{N}_3\text{O}_6$ deduced by HRMS, the substituent at C-1 had to be an amide instead of a carboxyl. Consequently, the structure of **1** was assigned as a new hydroxyphenazine-1-carboxamide glycoside and designed as endophenaside A (Figure 1).

Compounds 2–4 and 6 possess the basic phenazine skeleton in comparison with 1, and the structure elucidation was done by NMR and HRMS (Supplementary Data File 1; for physical properties of the new compounds and all supporting spectra for the structure elucidation, see Supplementary Data Files 2–3). Notably, Heine *et al.*²⁷ recently described endophenazines produced by *Kitasatospora* strain HK714, which were similar to but distinct from compound 1. Intensive spectroscopy data analysis for compounds 2–4 showed that their aglycone moieties were identical to those of previously described endophenazines,²⁷ except that compounds 2–4 carried an additional sugar moiety. Compound 6 (endophenazine F1) resembled




Figure 3 Selected NOE correlations (solid arrow) and coupling constants (dashed arrows) in the sugar moiety of compound 2.

endophenazine F, but contained a hydroxylated prenyl group at the N-5 position, with the hydroxyl group at a terminal methyl group.

Compound 5 (endophenazine E) featured a phenazine nucleus and a 6-deoxyhexopyranose sugar as shown by ¹H NMR. However, seven aromatic protons with overlapped and complicated coupling split patterns suggested a monosubstituted instead of a disubstituted pattern. The key HMBC correlation from sugar anomeric proton H-1' (δ_{H} 6.39) to C-11 (166.7) confirmed the connectivity of a sugar substituent to the phenazine core through a carbonyl group.

Table 3 Antimicrobial activity of purified phenazine derivatives 1–7

Compound	Inhibition zone (mm)	
	<i>Bacillus subtilis</i>	<i>Escherichia coli</i>
1	8	7
2	8	12
3	14	9
4	8	0
5	15	7
6	8	0
7	26	0
Ampicillin	30	21
Streptomycin	12	19
NC	0	0

Abbreviation: NC, negative control (methanol).
 For each compound, 25 μ l was spotted of a 2 mg ml⁻¹ solution in methanol.

Table 4 Gene organization of the phenazine biosynthetic gene cluster of *Kitasatospora* sp. MBT66 (Genbank accession number JAIY00000000)

ORF	Protein	Contig	Length (aa)	Annotation	Homologue in <i>Kitasatospora</i> sp.	
					HKI 714	Homology
ORF1	EpaA	182	303	Prenyltransferase	AHW81460.1	100%
ORF2	EpaB	182	345	Mevalonate kinase	AHW81461.1	100%
ORF3	EpaC	182	353	Diphosphomevalonate decarboxylase	AHW81462.1	100%
ORF4	EpaD	182, 329	413	Phosphomevalonate kinase	AHW81463.1	98%
ORF5	EpaE	329	360	Isopentenyl-diphosphate δ -isomerase	AHW81464.1	100%
ORF6	EpaF	329	352	HMG-CoA reductase	AHW81465.1	100%
ORF7	EpaG	329	391	HMG-CoA synthase	AHW81466.1	100%
ORF8	EpaH	329	51	Regulatory protein MerR	AHW81467.1	98%
ORF9	EpaI	329	207	Unknown function	AHW81468.1	99%
ORF10	EpaJ	329	160	Phenazine biosynthesis enzyme (PhzA/B ¹⁹)	AHW81469.1	100%
ORF11	EpaK	329	237	FMN-dependent oxidase (PhzG ¹⁹)	AHW81470.1	97%
ORF12	EpaL	329	278	<i>Trans</i> -2,3-dihydro-3-hydroxyanthranilate isomerase (PhzF ¹⁹)	AHW81471.1	99%
ORF13	EpaM	329	666	2-Amino-2-desoxy-isochorismate (ADIC) synthase (PhzE ¹⁹)	AHW81472.1	99%
ORF14	EpaN	329	207	2,3-Dihydro-3-hydroxy-anthranilate (DHHA) synthase (PhzD ¹⁹)	AHW81473.1	100%
ORF15	EpaO	329	391	3-Deoxy-D-arabino-heptulosonic acid 7-phosphate (DAHP) synthase (PhzC ⁴²)	AHW81474.1	99%
ORF16	EpaP	329	162	Enzyme of phenazine biosynthesis (PhzA/B)	AHW81475.1	99%
ORF17	EpaQ	329	421	Rhodocoxin reductase	AHW81476.1	99%
ORF18	EpaR	329	107	Putative rhodocoxin	AHW81477.1	100%
ORF19	EpaS	329	305	Transcriptional regulator	AHW81478.1	99%
ORF20	EpaT	329	431	Cytochrome d ubiquinol oxidase subunit I	AHW81479.1	99%
ORF21	EpaU	329	360	Cytochrome d ubiquinol oxidase subunit II	AHW81480.1	99%
ORF22	<i>orf1</i>	329	598	ABC transporter ATPase	AHW81481.1	100%
ORF23	<i>orf2</i>	329	569	ABC transporter	AHW81482.1	99%

Abbreviations: ADIC, 2-amino-2-desoxy-isochorismate; DAHP, 3-deoxy-D-arabino-heptulosonic acid 7-phosphate; DHHA, 2,3-dihydro-3-hydroxy-anthranilate; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA. Description of the genome sequencing and annotation has been detailed in Girard *et al.*²⁸ Proteins were named according to the gene cluster of *Kitasatospora* sp. HKI 714 (Genbank Accession KJ207079).²⁷ Literature references corresponding to the predicted functions are indicated in superscript.

Furthermore, endophenaside E (5) was found to be unstable and prone to methanolysis to generate 1-carbomethoxy phenazine (7) during NMR experiments (Supplementary Figure S1).

The relative stereochemistry of the 6-deoxyhexopyranose in compounds 1–5 was determined on the basis of NOE observations and coupling constants.^{30,32} The small coupling constant ($J_{1',2'}$ 1.5 Hz) between the anomeric proton and H-2' suggested that H-1' and H-2' were both in equatorial positions and assigned the relative configuration of H-1' to be α , since the NOE was not observed either between H-1' and H-3' or between H-1' and H-5'. The NOE observed between H-3' and H-5' as well as the coupling constant between H-4' and H-5' ($J_{4',5'}$ 9.5 Hz) indicated that they were axially oriented. Based on further comparison with NMR data reported previously,³⁰ 6-deoxyhexopyranose in compounds 1–5 was identified as an α -rhamnose (Figure 3). As mentioned above, few glycosylated phenazines have so far been found in nature, most of which are

rhamnosides with significant bioactivity.^{30,31} Endophenazines A (1) and C (3) are the first example for 2'-*O*-methylation of the rhamnose moiety in the phenazine glycosides.

The HMBC spectrum does not allow distinguishing between 1,6- or 1,9-disubstituted phenazine.^{27,30–33} Indeed, the prenyl- and the carboxyl group on the phenazine core of compounds 1–4, could be either 1,6- or 1,9-disubstituted. However, the presence of a 1,9-disubstituted pattern is deduced from previous analysis of the aglycone moiety²⁷ that is also present in compounds 2–4. Moreover, close scrutiny of *Kitasatospora* sp. MBT66 by UHPLC-Q-TOF analysis showed that *Kitasatospora* sp. MBT66 could in fact also produce most of the previously described aglycons (endophenazines) produced by *Kitasatospora* sp. HK714, albeit with a low yield (Supplementary Figure S2 and Supplementary Table S1). Conversely, the disubstitution pattern in compound 1 was tentatively proposed as [1,6-], which was deduced from the possible biosynthesis pathway (see below).




Figure 4 Proposed biogenesis of phenazine derivatives. Enzymes catalyzing the reaction correspond to Table 4. This biosynthesis pathway of phenazines was summarized according to references.^{19,20,35,42} Reactions leading to the formation of the phenazine core are highlighted by a dashed box, which includes spontaneous reaction without enzymatic catalysis.^{19,35} A yet uncharacterized glycosyltransferase and methyltransferase then give rise to the new glycosylated endophenazines (1–5) described in this study.

Antimicrobial activity of the endophenazines

Antimicrobial properties of compounds 1–7 were evaluated by agar diffusion assay, against the Gram-positive indicator strain *B. subtilis* 168 and the Gram-negative *E. coli* K12 (Table 3). Compound 5 showed highest antibiotic activity against both strains, while compounds 4 and 6 only inhibited *B. subtilis* and not *E. coli*. These antimicrobial activities are similar to the data published previously for the aglycones.²⁷ Remarkably, the glycosylation enhanced the activity of compounds 2 and 3 against Gram-negative *E. coli*, in contrast to what was reported for the corresponding aglycone. Taken together, our data show that the novel endophenazines described here have significant antimicrobial activity, whereby the glycosylation did not inhibit the bioactivity.

The phenazine biosynthetic gene cluster

Annotation of the genome sequence of *Kitasatospora* sp. MBT66 (Genbank accession number JAIY00000000²⁸) identified a gene cluster of around 25 kb that is likely responsible for the production of phenazine-type compounds. The gene products of the biosynthetic gene cluster (Table 4) were nearly identical to those of the endophenazine biosynthetic gene cluster of *Kitasatospora* sp. HKI 714 (*epaA-epaU*;²⁷ GenBank accession number: KJ207079). It was proposed that EpaA catalyzes the prenylation at C-9 and/or N-5 positions of phenazine-1-carboxylic acid, similar to the function of enzyme PpzP in *Streptomyces anulatus*,³⁴ which generated the [1,9-] substitution mode on the phenazine nucleus. From the perspective of biosynthesis, the formation of phenazine-1-carboxylic acid not only depends on the enzymes encoded by the gene cluster, but also involves spontaneous reaction without enzymatic catalysis.^{19,35} The carboxyl group derived from chorismate is likely cleaved by molecular oxygen through oxidative decarboxylation, which would be alternatively replaced by a hydroxyl group in the aqueous environment (Figure 4). This may explain why 6-hydroxyphenazine-1-carboxylic acid derivatives were frequently identified,^{30,31,36–38} while 9-hydroxyphenazine-1-carboxylic acid^{39,40} was less often found.

Besides the glycosylated endophenazines, we were able to show that *Kitasatospora* sp. MBT66 also produces small amounts of the same endophenazines as produced by *Kitasatospora* sp. HKI 714 (Supplementary Figure S2 and Supplementary Table S1). We expect that the two strains are closely related *kitasatosporae*, a genus closely related to *Streptomyces* in the family of *Streptomycetaceae*.⁴¹ This should be resolved by comparison of the genomes and phenotypic characteristics of the two strains. It is yet unclear which genes are responsible for the glycosylation of the endophenazine aglycones, as no such genes were found within or in close proximity of the *epa* gene cluster (Table 4). Therefore, the genes responsible for the transfer and methylation of the rhamnose moiety to either the carboxyl or the hydroxyl group of the phenazines should be located elsewhere on the chromosome. Research to identify the genes and enzymes responsible for the glycosylation of the endophenazines is currently in progress.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

The work was supported by a PhD Fellowship from the China Scholarship Council to CSW, and by grants from the Netherlands Technology Foundation (10467 and 11992) to GPvW. Physics data of compounds 1–6, Structure elucidation of compounds 2–4 and 6, instability of compound 5 in methanol, detection of endophenazines, as well as HRESIMS, IR, UV, 1D and 2D NMR spectra of compounds 1–6 are available.

- Giske, C. G., Monnet, D. L., Cars, O. & Carmeli, Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. *Antimicrob. Agents Chemother.* **52**, 813–821 (2008).
- Spellberg, B. *et al.* The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. *Clin. Infect. Dis.* **46**, 155–164 (2008).
- Rice, L. B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. *J. Infect. Dis.* **197**, 1079–1081 (2008).
- Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat. Rev. Drug Discov.* **6**, 29–40 (2007).
- Claessen, S., Rozen, D. E., Kuipers, O. P., Søgaard-Andersen, L. & van Wezel, G. P. Bacterial solutions to multicellularity: a tale of biofilms, filaments and fruiting bodies. *Nat. Rev. Microbiol.* **12**, 115–124 (2014).
- Flärdh, K. & Buttner, M. J. *Streptomyces* morphogenetics: dissecting differentiation in a filamentous bacterium. *Nat. Rev. Microbiol.* **7**, 36–49 (2009).
- Hopwood, D. A. *Streptomyces in Nature and Medicine: the Antibiotic Makers* (Oxford University Press, New York, 2007).
- Miyadoh, S. Research on antibiotic screening in Japan over the last decade: a producing microorganism approach. *Actinomycetol.* **7**, 100–106 (1993).
- Challis, G. L. & Hopwood, D. A. Synergy and contingency as driving forces for the evolution of multiple secondary metabolite production by *Streptomyces* species. *Proc. Natl Acad. Sci. USA* **100**, 14555–14561 (2003).
- Thomson, N. R. *et al.* Complete genome sequence of the model actinomycete *Streptomyces*. *Nature* **3**, 141–147 (2002).
- Ohnishi, Y. *et al.* Genome sequence of the streptomycin-producing microorganism *Streptomyces griseus* IFO 13350. *J. Bacteriol.* **190**, 4050–4060 (2008).
- Cruz-Morales, P. *et al.* The genome sequence of *Streptomyces lividans* 66 reveals a novel tRNA-dependent peptide biosynthetic system within a metal-related genomic island. *Genome Biol. Evol.* **5**, 1165–1175 (2013).
- Craney, A., Ozimok, C., Pimentel-Elardo, S. M., Capretta, A. & Nodwell, J. R. Chemical perturbation of secondary metabolism demonstrates important links to primary metabolism. *Chem. Biol.* **19**, 1020–1027 (2012).
- Van Wezel G. P., McKenzie N. L. & Nodwell J. R. Applying the genetics of secondary metabolism in model actinomycetes to the discovery of new antibiotics. *Methods Enzymol.* **458**, 117–141 (2009).
- Zhu, H., Sandiford, S. K. & van Wezel, G. P. Triggers and cues that activate antibiotic production by actinomycetes. *J. Ind. Microbiol. Biotechnol.* **41**, 371–386 (2014).
- Zhu, H. *et al.* Eliciting antibiotics active against the ESKAPE pathogens in a collection of actinomycetes isolated from mountain soils. *Microbiology* **160**, 1714–1725 (2014).
- Abken, H., Tietze, M. & Brodersen, J. Isolation and characterization of methanophenazine and function of phenazines in membrane-bound electron transport of *Methanoscarcina mazei* G61. *J. Bacteriol.* **180**, 2027–2032 (1998).
- Price-Whelan, A., Dietrich, L. E. P. & Newman, D. K. Rethinking 'secondary' metabolism: physiological roles for phenazine antibiotics. *Nat. Chem. Biol.* **2**, 71–78 (2006).
- Ahuja, E. G. *et al.* PhzA/B catalyzes the formation of the tricycle in phenazine biosynthesis. *J. Am. Chem. Soc.* **130**, 17053–17061 (2008).
- Laursen, J. B. & Nielsen, J. Phenazine natural products: biosynthesis, synthetic analogues, and biological activity. *Chem. Rev.* **104**, 1663–1686 (2004).
- Cholo, M. C., Steel, H. C., Fourie, P. B., Germishuizen, W. A. & Anderson, R. Clofazimine: current status and future prospects. *J. Antimicrob. Chemother.* **67**, 290–298 (2012).
- Cook, R. & Thomashow, L. Molecular mechanisms of defense by rhizobacteria against root disease. *Proc. Natl Acad. Sci. USA* **92**, 4197–4201 (1995).
- Hernandez, ME, Kappler, A & Newman, DK Phenazines and other redox-active antibiotics promote microbial mineral reduction. *Appl. Environ. Microbiol.* **70**, 921–928 (2004).
- Wang, Y., Kern, S. E. & Newman, D. K. Endogenous phenazine antibiotics promote anaerobic survival of *Pseudomonas aeruginosa* via extracellular electron transfer. *J. Bacteriol.* **192**, 365–369 (2010).
- Mavrodi, D. V., Blankenfeldt, W. & Thomashow, L. S. Phenazine compounds in fluorescent *Pseudomonas* spp. biosynthesis and regulation. *Annu. Rev. Phytopathol.* **44**, 417–445 (2006).
- van Wezel, G. P. *et al.* A new piece of an old jigsaw: glucose kinase is activated posttranslationally in a glucose transport-dependent manner in *Streptomyces coelicolor* A3(2). *J. Ind. Microbiol. Biotechnol.* **12**, 67–74 (2007).
- Heine, D., Martin, K. & Hertweck, C. Genomics-Guided Discovery of Endophenazines from *Kitasatospora* sp. HKI 714. *J. Nat. Prod.* **77**, 1083–1087 (2014).
- Girard, G. *et al.* Analysis of novel *kitasatosporae* reveals significant evolutionary changes in conserved developmental genes between *Kitasatospora* and *Streptomyces*. *Antonie Van Leeuwenhoek* **106**, 365–380 (2014).
- Romer, A. 1H NMR spectra of substituted phenazines. *Org. Magn. Reson* **19**, 66–68 (1982).
- Abdelfattah, M. S., Toume, K. & Ishibashi, M. Isolation and structure elucidation of izuminosides A-C: a rare phenazine glycosides from *Streptomyces* sp. IFM 11260. *J. Antibiot. (Tokyo)* **64**, 271–275 (2011).
- Rusman, Y., Oppégard, L. M., Hiasa, H., Gelbman, C. & Salomon, C. E. Solphenazines A-F, glycosylated phenazines from *Streptomyces* sp. strain DL-93. *J. Nat. Prod.* **76**, 91–96 (2013).

- 32 Kato, S., Shindo, K. & Yamagishi, Y. Phenazoviridin, a novel free radical scavenger from *Streptomyces* sp. Taxonomy, fermentation, isolation, structure elucidation and biological properties. *J. Antibiot. (Tokyo)* **46**, 1485–1493 (1993).
- 33 Krastel, P. & Zeeck, A. Endophenazines A-D, New Phenazine Antibiotics from the Athropod Associated Endosymbiont *Streptomyces anulatus*. II. Structure elucidation. *J. Antibiot. (Tokyo)* **55**, 801–806 (2002).
- 34 Saleh, O., Gust, B., Boll, B., Fiedler, H.-P. & Heide, L. Aromatic prenylation in phenazine biosynthesis: dihydrophenazine-1-carboxylate dimethylallyltransferase from *Streptomyces anulatus*. *J. Biol. Chem.* **284**, 14439–14447 (2009).
- 35 Rui, Z. *et al.* Insights into a divergent phenazine biosynthetic pathway governed by a plasmid-born esmeraldin gene cluster. *Chem. Biol.* **19**, 1116–1125 (2012).
- 36 Ohlendorf, B., Schulz, D., Erhard, A., Nagel, K. & Imhoff, J. F. Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a *Streptomyces* species. *J. Nat. Prod.* **75**, 1400–1404 (2012).
- 37 Abdelfattah, M. S., Kazufumi, T. & Ishibashi, M. Izumiphenazines A-C: isolation and structure elucidation of phenazine derivatives from *Streptomyces* sp. IFM 11204. *J. Nat. Prod.* **73**, 1999–2002 (2010).
- 38 Abdelfattah, M. S., Toume, K. & Ishibashi, M. Izumiphenazine D, a new phenazoquinoline N-oxide from *Streptomyces* sp. IFM 11204. *Chem. Pharm. Bull. (Tokyo)* **59**, 508–510 (2011).
- 39 Fotso, S. *et al.* Modified phenazines from an Indonesian *Streptomyces* sp. *J. Nat. Prod.* **73**, 472–575 (2010).
- 40 Gerber, N. New microbial phenazines. *J. Heterocycl. Chem.* **6**, 4–7 (1969).
- 41 Girard, G. *et al.* A novel taxonomic marker that discriminates between morphologically complex actinomycetes. *Open Biol* **3**, 130073 (2013).
- 42 Schneemann, I., Wiese, J., Kunz, A. L. & Imhoff, J. F. Genetic approach for the fast discovery of phenazine producing bacteria. *Mar. Drugs* **9**, 772–789 (2011).

Supplementary Information accompanies the paper on The Journal of Antibiotics website (<http://www.nature.com/ja>)